Medtronic stock is a "Buy" given its premium-margin medtech, diversification, accelerated growth, and undervalued shares.

Medtronic delivered $36.4B in revenue, the strongest growth in a decade, led by Cardiovascular and ablation solutions. Learn ...

Medtronic stock sits in an interesting middle ground, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing ...

Medtronic (MDT) ended the recent trading session at $83.87, demonstrating a +1.8% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.

Medtronic (MDT) ended the recent trading session at $78.23, demonstrating a -3.34% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.79%. At the same time ...

Medtronic recently reported strong results, highlighting impressive growth.

For years, investors questioned whether Medtronic was moving quickly and innovating enough. Now, the company is answering ...

Medical device makers Medtronic and Stryker are at the top of an industry on the move. Both are big names in the business, have pulled in double-digit gains to start the year, and are worth it for ...

Shares of Medtronic PLC MDT shed 3.34% to $78.23 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.79% to 7,499.36 and the ...

Needham: Medtronic reported revenues of $8.961 billion, topping consensus of $8.867 billion, and non-GAAP earnings of $1.36 per share, beating expectations of $1.31 per share, Matson said in a note.

Medtronic issued a voluntary global recall of its Octopus 4 Tissue Stabilizer after identifying an assembly issue during ...